Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta257
1 Guidance
1.1 Lapatinib in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women with metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).
1.2 Trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women with metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
1.3 Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor that is not recommended according to 1.1 or 1.2 should have the option to continue treatment until they and their clinicians consider it appropriate to stop.